Shilpa Medicare today said the US health regulator has issued an establishment inspection report (EIR) for its Raichur facility in Karnataka.
"We are in receipt of EIR (establishment inspection report) from the US Food and Drug Administration (USFDA) to our both API manufacturing facilities located at Raichur, Karnataka," Shilpa Medicare said in a BSE filing.
This inspection was carried out between January 16-19, 2018. The inspection has now been closed by the USFDA, it added.
USFDA gives EIR on closure of inspection of an establishment that is the subject of an FDA or FDA-contracted inspection.
Shares of Shilpa Medicare were trading 9.37 per cent higher at Rs 419.45 per scrip on the BSE.